Please login to the form below

Not currently logged in
Email:
Password:

Gattex

This page shows the latest Gattex news and features for those working in and with pharma, biotech and healthcare.

Alexion boosts rare disease portfolio with $8.4bn Synageva buy

Alexion boosts rare disease portfolio with $8.4bn Synageva buy

In recent weeks Shire agreed the takeover of NPS for $5.2bn, largely on the strength of rare disease therapies short bowel syndrome drug candidate Gattex (teduglutide) and Natpara (recombinant parathyroid

Latest news

  • Relief for Shire as FDA clears NPS' Natpara Relief for Shire as FDA clears NPS' Natpara

    placebo. Natpara is NPS' second approved product after Gattex/Revestive (teduglutide), a GLP-2 analogue used for the long-term treatment of short bowel syndrome in adults that is expected to

  • Shire signs deal to buy NPS for $5.2bn Shire signs deal to buy NPS for $5.2bn

    Shire chief executive Flemming Ornskov said that the combined company would be able to drive sales of NPS' rare gastrointestinal (GI) disease therapy Gattex/Revestive (teduglutide), a GLP-2 analogue approved ... The companies were also not prepared to

  • FDA clears six new drugs in time for the new year FDA clears six new drugs in time for the new year

    Finally, the FDA issued an approval for the use of NPS Pharmaceuticals' Gattex (teduglutide) as a treatment for adults with short bowel syndrome (SBS) who need additional nutrition from intravenous

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    NPS/Shire. NPS specialises in rare diseases including Gattex [teduglutide] for the treatment of short bowel syndrome.

  • Pharma deals during January 2015 Pharma deals during January 2015

    Paying $46 per share (a 51% share price premium), this deals brings Gattex (teduglutide) used in the long-term treatment of adults with short bowel syndrome into the Shire portfolio and

  • Pharma deals during March 2013 Pharma deals during March 2013

    The company is preparing to launch teduglutide as Gattex in the US later in 2013 and is also planning to submit a biologic license application to the FDA for PTH

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....